Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent

ClinicalTrials.gov ID: NCT07843732

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07843732. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Adult Patients of African Descent With Biopsy-proven Central Centrifugal Cicatricial Alopecia (CCCA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study evaluated the safety and efficacy of baricitinib 4 mg daily in adults of African descent with biopsy-proven central centrifugal cicatricial alopecia, a scarring alopecia for which no FDA-approved treatment exists. Participants received open-label baricitinib for 52 weeks at four sites in the United States. Scalp hair loss was assessed by the Investigator Global Assessment at baseline and by the Investigator Re-Assessment Score at each post-baseline visit, with patient-reported quality of life and scalp symptom measures collected in parallel.

Study identification

NCT ID: NCT07843732
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Raven Clinical Research; Network
Enrollment: 27 participants

Conditions and interventions

Conditions

Central Centrifugal Cicatricial Alopecia

Interventions

Baricitinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 22, 2024 (Actual)
Primary completion: Apr 28, 2026 (Actual)
Completion: Apr 28, 2026 (Actual)
Last update posted: Sep 28, 2026

2024 – 2026

United States locations

U.S. sites: 4
U.S. states: 3
U.S. cities: 4

Facility	City	State	ZIP	Site status
Site 02	Marriottsville	Maryland	21104	—
Site 03	Fairfax	Virginia	22033	—
Site 01	McLean	Virginia	22102	—
Site 04	Burlington	Wisconsin	53105	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07843732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 28, 2026 · Synced Nov 14, 2026